149 related articles for article (PubMed ID: 36785565)
41. Adjuvant brachytherapy for oral squamous cell carcinomas: a single-center experience comparing low-dose and pulsed-dose-rate techniques.
Mattei P; Chabrillac E; Cabarrou B; Dupret-Bories A; Vergez S; Sarini J; Lopez R; Piram L; Brun T; Modesto A
Strahlenther Onkol; 2022 Feb; 198(2):150-158. PubMed ID: 34786604
[TBL] [Abstract][Full Text] [Related]
42. LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models.
King CR
Brachytherapy; 2002; 1(4):219-26. PubMed ID: 15062170
[TBL] [Abstract][Full Text] [Related]
43. Long-term results (10 years) of intensive breast conserving therapy including a high-dose and large-volume interstitial brachytherapy boost (LDR/HDR) for T1/T2 breast cancer.
Resch A; Pötter R; Van Limbergen E; Biber E; Klein T; Fellner C; Handl-Zeller L; Langbauer G; Schürer-Waldheim H; Staffen A; Jakesz R; Kubista E; Lehr S; Seitz W
Radiother Oncol; 2002 Apr; 63(1):47-58. PubMed ID: 12065103
[TBL] [Abstract][Full Text] [Related]
44. Comparative dosimetrical analysis of intensity-modulated arc therapy, CyberKnife therapy and image-guided interstitial HDR and LDR brachytherapy of low risk prostate cancer.
Fröhlich G; Ágoston P; Jorgo K; Stelczer G; Polgár C; Major T
Rep Pract Oncol Radiother; 2021; 26(2):196-202. PubMed ID: 34211769
[TBL] [Abstract][Full Text] [Related]
45. Survey of the use of the ICRU 38 in recording and reporting cervical cancer brachytherapy.
Pötter R; Van Limbergen E; Gerstner N; Wambersie A
Radiother Oncol; 2001 Jan; 58(1):11-8. PubMed ID: 11165676
[TBL] [Abstract][Full Text] [Related]
46. Electron and high-dose-rate brachytherapy boost in the conservative treatment of stage I-II breast cancer first results of the randomized Budapest boost trial.
Polgár C; Fodor J; Orosz Z; Major T; Takácsi-Nagy Z; Mangel LC; Sulyok Z; Somogyi A; Kásler M; Németh G
Strahlenther Onkol; 2002 Nov; 178(11):615-23. PubMed ID: 12426672
[TBL] [Abstract][Full Text] [Related]
47. High-dose-rate (HDR) or pulsed-dose-rate (PDR) perioperative interstitial intensity-modulated brachytherapy (IMBT) for local recurrences of previously irradiated breast or thoracic wall following breast cancer.
Niehoff P; Dietrich J; Ostertag H; Schmid A; Kohr P; Kimmig B; Kovács G
Strahlenther Onkol; 2006 Feb; 182(2):102-7. PubMed ID: 16447017
[TBL] [Abstract][Full Text] [Related]
48. Adjuvant high-dose-rate and low-dose-rate brachytherapy with external beam radiation in soft tissue sarcoma: a comparison of outcomes.
Pohar S; Haq R; Liu L; Koniarczyk M; Hahn S; Damron T; Aronowitz JN
Brachytherapy; 2007; 6(1):53-7. PubMed ID: 17284387
[TBL] [Abstract][Full Text] [Related]
49. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
50. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy.
Georg D; Hopfgartner J; Gòra J; Kuess P; Kragl G; Berger D; Hegazy N; Goldner G; Georg P
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):715-22. PubMed ID: 24521685
[TBL] [Abstract][Full Text] [Related]
51. 3D-image-guided HDR-brachytherapy versus 2D HDR - brachytherapy after external beam radiotherapy for early T-stage nasopharyngeal carcinoma.
Ren Y; Zhao Q; Liu H; Huang Y; Wang Z; Cao X; Teh BS; Wen B
BMC Cancer; 2014 Nov; 14():894. PubMed ID: 25432818
[TBL] [Abstract][Full Text] [Related]
52. The optimal fraction size in high-dose-rate brachytherapy: dependency on tissue repair kinetics and low-dose rate.
Sminia P; Schneider CJ; Fowler JF
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):844-9. PubMed ID: 11849810
[TBL] [Abstract][Full Text] [Related]
53. Salvage brachytherapy for locally recurrent prostate cancer after single-fraction 19 Gy high-dose-rate brachytherapy: toxicity, prostate-specific antigen kinetics, and cancer control.
Mayrata E; Espinosa JM; Büchser D; Casquero F; Suárez F; González A; Minguez P; Pérez JF; Miguel IS; Cacicedo J; Gómez-Iturriaga A
J Contemp Brachytherapy; 2021 Feb; 13(1):12-17. PubMed ID: 34025731
[TBL] [Abstract][Full Text] [Related]
54. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract][Full Text] [Related]
55. Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: A comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy.
Henríquez López I; González-San Segundo C; Vegas JO; Gutierrez C; Hervas A; Cabeza Rodriguez MÁ; Valero Albarrán J; Rodríguez Villalba S; Álvarez Gonzalez A; Sancho Pardo G; Zapatero A; Álvaro PC
Radiother Oncol; 2019 Dec; 141():156-163. PubMed ID: 31570236
[TBL] [Abstract][Full Text] [Related]
56. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
57. Perioperative hyperfractionated high-dose rate brachytherapy for the treatment of soft tissue sarcomas: multicentric experience.
Petera J; Soumarová R; Růzicková J; Neumanová R; Dusek L; Sirák I; Macingová Z; Paluska P; Kasaová L; Hodek M; Vosmik M
Ann Surg Oncol; 2010 Jan; 17(1):206-10. PubMed ID: 19711130
[TBL] [Abstract][Full Text] [Related]
58. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
[TBL] [Abstract][Full Text] [Related]
59. High dose rate brachytherapy in the management of anal cancer: A review.
Ali ZS; Solomon E; Mann P; Wong S; Chan KKW; Taggar AS
Radiother Oncol; 2022 Jun; 171():43-52. PubMed ID: 35381275
[TBL] [Abstract][Full Text] [Related]
60. Low-dose-rate brachytherapy is superior to high-dose-rate brachytherapy for bladder cancer.
Pos FJ; Horenblas S; Lebesque J; Moonen L; Schneider C; Sminia P; Bartelink H
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):696-705. PubMed ID: 15183473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
